Psychedelics in Depression

Introduction and Clinical Context

In recent years, classic psychedelics such as psilocybin and ayahuasca have sparked renewed interest in the treatment of treatment-resistant major depression and depressive syndromes associated with terminal illnesses. These substances, which had been excluded from clinical research for decades, are now emerging as potential therapeutic tools within controlled psychotherapeutic protocols, offering an innovative and profound approach to psychological suffering.

Current studies do not advocate a strictly "pharmacological" use but rather the integration of psychedelic administration within a structured therapeutic pathway, including preparation, assisted administration, and post-experience integration. This approach is referred to as psychedelic-assisted psychotherapy.

Mechanism of Action

Classic psychedelics act as partial agonists of the serotonin 5-HT2A receptor, which is particularly expressed in the prefrontal cortex and associative areas of the brain. Their activation induces a state of increased cerebral entropy, leading to the temporary disruption of habitual functional connectivity patterns (default mode network) and promoting greater cognitive flexibility.

This neurophysiological state facilitates cognitive-affective restructuring and may induce intense subjective experiences (altered states of consciousness, visions, insights) that—when properly contextualized—enable deep processing of trauma, dysfunctional beliefs, and rigid depressive patterns.

Main Compounds and Areas of Research

Psilocybin

Psilocybin, extracted from hallucinogenic mushrooms of the genus Psilocybe, is the most extensively studied substance. Administered as a single oral dose (20–30 mg) in a controlled environment, it has demonstrated rapid and sustained efficacy in treatment-resistant depression, with clinical improvements lasting for several months. Results are particularly promising in the treatment of depression associated with terminal cancer, where it has been shown to reduce anxiety, despair, and anhedonia.

Ayahuasca

Ayahuasca is an Amazonian brew made from Banisteriopsis caapi and Psychotria viridis, containing DMT (dimethyltryptamine) and natural MAO inhibitors. Its action is similar to that of psilocybin but more intense and shorter in duration, with powerful visual, somatic, and introspective effects. Controlled clinical studies have shown a rapid reduction of depressive symptoms after just a single administration.

Therapeutic Context and Safety

Psychedelics are not administered in isolation but within a structured therapeutic setting that includes:

• Psychological preparation: information sharing, establishment of the therapeutic alliance, and goal setting;
• Assisted administration: protected environment, presence of therapists, continuous monitoring;
• Post-experience integration: elaboration of the experience, reformulation of its meaning, and stabilization of changes.

Side effects are generally transient and dose-dependent, including anxiety, nausea, dysphoria, and temporary confusion. Serious adverse reactions are rare in controlled clinical settings. However, psychedelics are contraindicated in patients with a personal or family history of psychosis, bipolar disorder, or psychotic vulnerability.

Current Research Status and Future Perspectives

Clinical trials with psilocybin are currently in phase III for treatment-resistant depression and in advanced phases for anxiety-related disorders and substance use disorders. The FDA has granted breakthrough therapy designation for psilocybin in depression, accelerating its development pathways.

Integration with psychotherapeutic techniques appears to be crucial for maintaining the benefits. It is hypothesized that these interventions not only alleviate symptoms but also profoundly restructure self-perception, the sense of connection, and the outlook on life.

References
1. Carhart-Harris RL et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32(7):725–731.
2. Griffiths RR et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. J Psychopharmacol. 2016;30(12):1181–1197.
3. Ross S et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer. J Psychopharmacol. 2016;30(12):1165–1180.
4. Palhano-Fontes F et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression. Psychol Med. 2019;49(4):655–663.
5. Davis AK et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78(5):481–489.
6. Goodwin GM et al. Single-dose psilocybin for a treatment-resistant episode of major depression. New Engl J Med. 2022;387(17):1637–1648.
7. Anderson T et al. Psychedelic integration: an analysis of the concept and its practice. J Humanist Psychol. 2020;60(4):392–417.
8. Reiff CM et al. Psychedelics and psychedelic-assisted psychotherapy. Am J Psychiatry. 2020;177(5):391–410.
9. Johnson MW et al. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603–620.
10. Gukasyan N, Davis AK. Psychedelics in the treatment of depression: current evidence and therapeutic potential. Ther Adv Psychopharmacol. 2021;11:1–18.